Farletuzumab in lung cancer

Lung Cancer

Volumn 80, Issue 1, 2013, Pages 15-18

  Thomas, Anish ^a   Maltzman, Julia ^b   Hassan, Raffit ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Morphotek Inc   (United States)

Author keywords

Adenocarcinoma; Farletuzumab; Folate receptor ; Immunohistochemistry; Monoclonal antibody; Non small cell lung cancer

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT; FARLETUZUMAB; FOLATE RECEPTOR 1;

AREA UNDER THE CURVE; CHILL; DIARRHEA; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; FOLATE RECEPTOR 1; FOLIC ACID; HUMANS; LUNG NEOPLASMS;

EID: 84875242166     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.12.021     Document Type: Review

References (36)

1. Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007, 2:706-714.
2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Alberti W., Anderson G., Bartolucci A., Bell D., Villalba J.B., Brodin O., et al. Chemotherapy in non-small-cell lung-cancer - a metaanalysis using updated data on individual patients from 52 randomized clinical-trials. Br Med J 1995, 311:899-909.
4. Cancer Incidence - Surveillance, epidemiology, and end results (SEER) registries research data 2011, National Cancer Institute, Cancer Statistics Branch, Bethesda, MD.
5. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
6. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
7. Sequist L.V., Heist R.S., Shaw A.T., Fidias P., Rosovsky R., Temel J.S., et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011, 22:2616-2624.
8. Cohen M.H., Johnson J.R., Wang Y.C., Sridhara R., Pazdur R. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 2005, 10:363-368.
9. Matherly L.H., Hou Z., Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 2007, 26:111-128.
10. Elnakat H., Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004, 56:1067-1084.
11. Mantovani L.T., Miotti S., Menard S., Canevari S., Raspagliesi F., Bottini C., et al. Folate binding-protein distribution in normal-tissues and biological-fluids from ovarian-carcinoma patients as detected by the monoclonal-antibodies Mov18 and Mov19. Eur J Cancer 1994, 30A:363-368.
12. Bueno R., Appasani K., Mercer H., Lester S., Sugarbaker D. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J. Thorac Cardiovasc Surg 2001, 121:225-233.
13. Wu M., Gunning W., Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemol Biomarkers Prev 1999, 8:775-782.
14. Franklin W.A., Waintrub M., Edwards D., Christensen K., Prendegrast P., Woods J., et al. New anti-lung-cancer antibody cluster-12 reacts with human folate receptors present on adenocarcinoma. Int J Cancer 1994, 8:89-95.
15. Lu Y.J., Low P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 2002, 54:675-693.
16. Leamon C.P., Low P.S. Delivery of macromolecules into living cells - a method that exploits folate receptor endocytosis. Proc Natl Acad Sci USA 1991, 88:5572-5576.
17. Edelman M.J., Bonomi P., Harb W., Pal S., Boccia R., Kraut M., et al. The co-development of a folate receptor targeted drug conjugate vintafolide (EC145) and a folate receptor targeted imaging agent 99mTc-etarfolatide (EC20) in the treatment of advanced adenocarcinoma NSCLC. 3rd European lung cancer conference in Geneva, Switzerland April; 2012.
18. Konner J.A., Bell-McGuinn K.M., Sabbatini P., Hensley M.L., Tew W.P., Pandit-Taskar N., et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 2010, 16:5288-5295.
19. Nunez M.I., Behrens C., Woods D.M., Lin H., Suraokar M., Kadara H., et al. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and mutation. J Thorac Oncol 2012, 7:833-840.
20. Iwakiri S., Sonobe M., Nagai S., Hirata T., Wada H., Miyahara R. Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. Ann Surg Oncol 2008, 15:889-899.
21. O'Shannessy D.J., Yu G., Smale R., Fu Y.S., Singhal S., Thiel R.P., et al. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget 2012, 3:414-425.
22. Kikuchi T., Daigo Y., Katagiri T., Tsunoda T., Okada K., Kakiuchi S., et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003, 22:2192-2205.
23. Garber M.E., Troyanskaya O.G., Schluens K., Petersen S., Thaesler Z., Pacyna-Gengelbach M., et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001, 98:13784-13789.
24. Bhattacharjee A., Richards W.G., Staunton J., Li C., Monti S., Vasa P., et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001, 98:13790-13795.
25. Brown Jones M., Neuper C., Clayton A., Mariani A., Konecny G., Thomas M.B., et al. Rationale for folate receptor alpha targeted therapy in " high risk" endometrial carcinomas. Int J Cancer 2008, 123:1699-1703.
26. Hartmann L.C., Keeney G.L., Lingle W.L., Christianson T.J.H., Varghese B., Hillman D., et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 2007, 121:938-942.
27. Toffoli G., Russo A., Gallo A., Cernigoi C., Miotti S., Sorio R., et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer 1998, 79:121-126.
28. Parker N., Turk M.J., Westrick E., Lewis J.D., Low P.S., Leamon C.P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005, 338:284-293.
29. Garinchesa P., Campbell I., Saigo P.E., Lewis J.L., Old L.J., Rettig W.J. Trophoblast and ovarian-cancer antigen-Lk26 - sensitivity and specificity in immunopathology and molecular-identification as a folate-binding protein. Am J Pathol 1993, 142:557-567.
30. Nicolaides N.C., Ebel W., Kline B., Chao Q.M., Routhier E., Sass P.M., et al. Morphogenics as a tool for target discovery and drug development. Ann NY Acad Sci 2005, 1059:86-96.
31. Ebel W., Routhier E.L., Foley B., Jacob S., McDonough J.M., Patel R.K., et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 2007, 7:6.
32. Kamen B.A., Smith A.K. Farletuzumab, an anti-folate receptor alpha antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro. Cancer Chemother Pharmacol 2012, 70:113-120.
33. Smith-Jones P.M., Pandit-Taskar N., Cao W., O'Donoghue J., Philips M.D., Carrasquillo J., et al. Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. Nucl Med Biol 2008, 35:343-351.
34. Sasaki Y., Miwa K., Yamashita K., Fujiwara K., Katsumata N., Fujiwara Y., et al. Phase I, and pharmacokinetic study of farletuzumab in solid tumors, phase I and pharmacokinetic study of farletuzumab in solid tumors. J Clin Oncol 2012, 30(Suppl.). [abstr 3084].
35. Jelovac D., Armstrong D.K., Weil S., Phillips M., Schwartz B.M., Estes J.M., et al. Phase I, safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian cancer (EOC), phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian cancer (EOC). J Clin Oncol 2011, 29(Suppl.). [abstr 5056].
36. White A.J., Coleman R.L., Armstrong D.K., Glenn D., Bicher A., Richards D.A., et al. Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: final data from a multicenter phase II study. J Clin Oncol 2010, 28(Suppl.). [abstr 5001].